In Vivo – Biopharma R&D, December 2015
Has biopharma R&D productivity increased since last year’s analysis? (See “Value-Based Pharma R&D Productivity: Is There A Sweet Spot?” — IN VIVO, June 2014.) Who are the new entries into the elite top-five group, and who has dropped out? Is the acceleration in innovation, indicated by the increased number of breakthrough designations and FDA approvals, a direct result of improving R&D productivity in our sample of the 30 largest biopharmas?